The innovation arm of a pharmaceutical company has signed up to work with the Singapore Economic Development Board to unlock life sciences potential.
Johnson & Johnson Innovation – JLABS helps early-stage companies to accelerate their discoveries into medicines, medical technologies and healthcare solutions.
It is a no-strings-attached model, which means innovators are free to develop their science and technology while holding on to their intellectual property.
“At Johnson & Johnson Innovation, we source and cultivate the world’s most promising, early-stage healthcare innovation wherever it originates,” said executive vice president William N Hait.
“We are thrilled to partner with EDB to advance the thriving life sciences community in Singapore and help unleash the potential of healthcare innovation in the Asia Pacific region for the rest of the world.”
This collaboration demonstrates the ongoing commitment of Johnson & Johnson to enable and accelerate the best science and technology in the Asia Pacific region, the company said.
It builds on the success of JLABS’ no-strings-approach and experience, as well as its reputation as the largest global network of life science startups, investors, and corporate partners, it added.
“The needs of the next generation of global innovators, potential partners, and early-stage companies are changing rapidly,” said Johnson & Johnson Innovation – JLABS global head Melinda Richter.
“And Johnson & Johnson is committed to pioneering new approaches to address them, like this significant collaboration with the Economic Development Board.”
She said it exemplifies the company’s role as an innovation, talent, economic and venture developer with a mission to empower its partners with the knowledge, experience, networks and practical frameworks.
Johnson & Johnson Innovation – JLABS and the Economic Development Board will be co-hosting a symposium in Singapore before the end of the year.
